Antibody capable of bonding with LINC0266-1

A technology of antibodies and peptides, applied in the field of cancer diagnosis and treatment, can solve the problems of non-existence of antibodies, and achieve the effects of increasing the positive rate, high mortality rate, and short survival period

Active Publication Date: 2019-03-26
THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Therefore, there is no antibody capable of specifically binding to the LINC00266-1 polypeptide in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody capable of bonding with LINC0266-1
  • Antibody capable of bonding with LINC0266-1
  • Antibody capable of bonding with LINC0266-1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Prepare the anti-LINC00266-1 polypeptide antibody, and detect the titer of the prepared anti-LINC00266-1 polypeptide antibody, the specific operation process is as follows:

[0058] (1) The designed antigenic epitope peptide 1 (shown in SEQ ID NO: 2) and antigenic epitope peptide 2 (shown in SEQ ID NO: 3) against the LINC00266-1 polypeptide were synthesized by chemical synthesis (Gill Biochemical (Shanghai) Co., Ltd.), then the synthetic epitope peptide 1 and antigen epitope peptide 2 were coupled with keyhole limpet hemocyanin as immune antigen 1 and immune antigen 2, and were analyzed by high pressure liquid chromatography (HPLC). The immune antigen is separated and purified to make its purity >85%.

[0059] Take 2 healthy New Zealand rabbits with body weight not less than 2kg, named as the rabbit of antigenic epitope peptide 1 and the rabbit of antigenic epitope peptide 2 respectively. 2 to 3 ml of blood from the above-mentioned rabbit ear arteries were collected, a...

Embodiment 2

[0074] Anti-LINC00266-1 antibodies prepared based on epitope peptide 1 and anti-LINC00266-1 antibodies prepared based on epitope peptide 2 were used for specific detection experiments on LINC00266-1 polypeptides. The specific steps are as follows:

[0075] The first step is to construct the LINC00266-1-GFP fusion gene expression vector. First, site-directed mutation of the wild-type GFP (GFPwt) gene translation promoter ATGGTG sequence to ATTGTT (GFPmut). Therefore, the translation of the GFP gene is destroyed, and the translation promoter ATG on the LINC00266-1 gene is used for translation, thereby expressing and producing the LINC00266-1-GFP fusion protein. After transfecting HeLa cells (ATCC, Number: CCL-2) with liposome Lipo2000 (Life technology) for 24 hours, the cells were collected and lysed to prepare protein samples. Using the anti-LINC00266-1 polypeptide antibody prepared based on antigenic epitope peptide 1 and the anti-LINC00266-1 polypeptide antibody prepared bas...

Embodiment 3

[0080] Using the Western blotting method, the anti-LINC00266-1 antibody prepared by the present invention was used to detect the expression level of the LINC00266-1 polypeptide in colon cancer cells with different invasion and metastasis potentials from the same source. The specific process is as follows:

[0081] Two pairs of colon cancer cells SW480 and SW620 (ATCC, Number: CCL-228 and CCL-227, respectively), HTC-116 (ATCC, Number: CCL-247) and HTC-116high (this cell Established by the previous screening in our laboratory), the cells were lysed to prepare protein samples. Using the Western blotting method, the anti-LINC00266-1 polypeptide antibody prepared by the present invention was used to detect the difference in the level of LINC00266-1 polypeptide between the paired cells. The result is as image 3 As shown, the level of LINC00266-1 polypeptide was significantly up-regulated in colon cancer cells SW620 and HTC-116high with high invasion and metastasis potential. In t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the fields of the diagnosis and treatment of cancers and discloses an antibody capable of bonding with LINC0266-1. The antibody can be used for detecting or diagnosing tumorsor evaluating and monitoring prognosis conditions of patients.

Description

technical field [0001] The present invention relates to the field of diagnosis and treatment of cancer, in particular to an antibody capable of binding LINC00266-1 polypeptide. Background technique [0002] lncRNA LINC00266-1 is annotated as a long-chain non-coding RNA in the NCBI database of the National Institutes of Health. It is currently believed that lncRNA LINC00266-1 cannot encode proteins or polypeptides. [0003] Therefore, there is no antibody capable of specifically binding to the LINC00266-1 polypeptide in the prior art. Contents of the invention [0004] The present invention relates to an isolated binding protein comprising an antigen binding domain, which can specifically bind LINC00266-1 polypeptide; the amino acid sequence of the LINC00266-1 polypeptide is shown in SEQ ID NO:1. [0005] According to another aspect of the present invention, the present invention also relates to the use of the above-mentioned binding protein in the preparation of reagents ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18G01N33/574
CPCC07K16/18G01N33/57484G01N2333/47
Inventor 晏光荣朱嵩王继重
Owner THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap